Monday 9 November 2026 Export TXMD’s income statement to Excel — free account

TherapeuticsMD, Inc.

TXMD

Healthcare Drug Manufacturers Specialty & Generic

TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024.

Revenue: −8.72%
EPS: −80.0%
Free cash flow: +104.5%

Quarter to June 2026, against a year earlier

Insider buying

1.74 0.03 +1.75%

Follow TXMD

Alert me

Market cap: $20.1M
P/E: n/m
Fwd P/E: 18.9×
Dividend yield: —
F-score: 6/9
ROIC: −13.8%
Net debt / EBITDA: 2.3×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net bought: $14.0K
Trades: 0 sells · 1 buy
Ownership: 8.42%

Capital & Financial Ratios $m

Size

Market Cap 20

Revenue ttm 3

Net income ttm 0

Free cash flow ttm 3

Net debt Q (9)

Valuation

P/E n/m

Forward P/E 18.9

Price / sales 6.2

Forward P/S Powerpack

Price / FCF 7.4

Price / book 0.7

Financial health

Current ratio Q 3.2

Debt / equity Q n/m

Interest coverage Q (287.3)

Growth

Revenue growth Q −8.7%

Operating income growth Q −17.4%

EPS, this year —

EPS, next year A —

Revenue, next year A +422.4%

EPS, past 5 yrs —

EPS, next 5 yrs A +17.6%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 27.15%

10-year low 10-year high

P/B against its own 10 years 18.33%

10-year low 10-year high

EV/Sales against its own 10 years 70.88%

10-year low 10-year high

EV/FCF against its own 10 years 40.56%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	7	9
Receivables	3	4	4	3
Inventory	—	—	—	—
Other	4	4	3	4
	12	12	14	16

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(17.28%)	(45.84%)	(64.91%)
Cash Flow	0.00%	0.00%	(35.99%)
Earnings	0.00%	0.00%	0.00%
Book Value	(8.18%)	0.00%	(8.55%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY22 Estimate −2.04 Actual −3.13

−5.12 −4.25 −3.38 −2.51 −1.64

Q4 FY21 Miss −1.50

Q1 FY22 Miss −1.22

Q2 FY22 Beat +0.89

Q3 FY22 Miss −1.09

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY21	−3.00	−4.50	Miss by 1.50
Q1 FY22	−3.50	−4.72	Miss by 1.22
Q2 FY22	−3.04	−2.15	Beat by 0.89
Q3 FY22	−2.04	−3.13	Miss by 1.09

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	0.01	—	—	—
’25	(0.06)	0.05	0.01	(0.05)	(0.05)
’24	(0.06)	(0.09)	(0.05)	0.02	(0.19)
’23	(0.37)	(0.24)	(0.32)	(0.06)	(0.98)
’22	(5.69)	12.39	(3.13)	7.94	11.96
’21	(5.50)	(5.50)	(5.50)	(5.00)	(21.50)
’20	(10.50)	(9.50)	(6.00)	(7.50)	(36.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	0	1	1	1	3
’24	0	0	1	1	2
’23	0	0	0	1	1
’22	1	0	0	69	70
’21	20	23	25	(66)	3
’20	12	11	19	23	65

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	0	1	0	2
’24	0	1	0	0	1
’23	(9)	(3)	(6)	(5)	(23)
’22	(18)	(21)	18	30	9
’21	(38)	(27)	(38)	48	(55)
’20	(39)	(56)	(34)	(30)	(159)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	0	1	0	2
’24	0	1	0	0	1
’23	(9)	(3)	(6)	(5)	(23)
’22	(18)	(21)	18	30	9
’21	(39)	(27)	(38)	46	(57)
’20	(40)	(56)	(34)	(31)	(161)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	19	17	16	50	65	3	70	1	2	3	3		(18.6%)	—	—	—	—
	Gross margin, %	78.38	84.28	83.00	87.24	75.37	45.51	98.00	100.00	100.00	100.00	100.00		+21.6 pt	Powerpack TherapeuticsMD, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(90)	(77)	(133)	(176)	(184)	(79)	1	(8)	(2)	(1)	0		(42.1%)
	EBT margin, %	(464.32)	(458.50)	(823.73)	(354.79)	(282.90)	(3,082.20)	1.54	(594.62)	(133.05)	(21.61)	(8.04)		+442.7 pt
	Net income	(90)	(77)	(133)	(176)	(184)	(172)	112	(10)	(2)	(1)	0		(43.0%)
Per share, $
Per share, $	Revenue	4.94	4.08	3.58	10.08	11.77	0.32	7.75	0.12	0.15	0.26	0.28		(27.9%)
	Earnings	(23.00)	(18.50)	(29.50)	(36.00)	(36.00)	(21.50)	12.41	(0.98)	(0.19)	(0.05)	(0.02)		(49.4%)
	Cash flow	(17.63)	(18.53)	(23.73)	(33.63)	(28.93)	(6.93)	1.04	(2.21)	0.10	0.21	0.27		n/m
	Capex	(0.32)	(0.20)	(4.74)	(4.85)	(0.29)	(0.28)	(0.04)	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(17.95)	(18.73)	(28.47)	(38.48)	(29.22)	(7.21)	1.00	(2.21)	0.10	0.21	0.27		n/m
	Book value	32.51	31.60	21.67	1.87	(22.49)	(11.76)	3.89	2.81	2.37	2.32	2.34		(25.4%)
	Shares, m	4	4	5	5	6	8	9	10	12	12	12		+12.8%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00	0.00		0.1
	P/S	60.48	76.81	53.25	12.01	5.14	55.01	0.81	18.68	5.63	6.24	6.16		29.4
	P/B	9.18	9.92	8.79	64.79	0.00	0.00	1.61	0.83	0.36	0.70	0.74		9.6
	EV/Sales	53.68	69.23	47.77	12.72	7.60	169.70	3.89	219.16	153.43	91.57	84.49		82.9
	EV/FCF	(14.76)	(15.09)	(6.00)	(3.33)	(3.06)	(7.61)	30.33	(12.16)	340.30	133.16	101.54		44.2
Cash, $m
Cash, $m	Operating cash flow	(69)	(76)	(107)	(166)	(159)	(55)	9	(23)	1	2	3		n/m
	Capex	(1)	(1)	(21)	(24)	(2)	(2)	0	—	—	—	0		(18.8%)
	Free cash flow	(70)	(77)	(128)	(190)	(161)	(57)	9	(23)	1	2	3		n/m
Balance, $m
Balance, $m	Working capital	124	126	146	155	69	(133)	9	5	7	10	11		(24.7%)
	Net debt	(132)	(127)	(88)	35	159	123	(49)	(4)	(5)	(7)	(9)		(27.3%)
	Shareholders’ equity	127	130	98	9	(124)	(94)	35	29	27	27	27		(15.9%)
Returns, %
Returns, %	ROA	(83.14)	(53.85)	(74.67)	(73.71)	(82.00)	(98.22)	86.17	(15.37)	(5.31)	(1.49)	(0.57)		+81.7 pt
	ROIC	0.00	(1,749.59)	(875.89)	(212.33)	(274.11)	(167.23)	0.00	(21.34)	(17.12)	(14.15)	(13.77)		(14.1) pt
	ROE	(94.33)	(59.77)	(116.62)	(330.09)	319.73	158.45	(383.04)	(31.90)	(7.70)	(2.10)	(0.80)		+92.2 pt
People
People	Employees	159	173	241	348	400	416	1	1	1	1	—		(43.1%)
	Revenue/emp, $m	0.12	0.10	0.07	0.14	0.16	0.01	69.96	1.30	1.76	3.02	—		+42.9%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SCYX SCYNEXIS, Inc.	$34.8M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
RMTI Rockwell Medical, Inc.	$31.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
IXHL Incannex Healthcare Inc.	$28.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.6M	— (loss-making)	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
CPHI China Pharma Holdings, Inc.	$24.5M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
TXMD TherapeuticsMD, Inc.	$20.1M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)
AYTU Aytu BioPharma, Inc.	$19.9M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
OPTH Optimi Health Corp.	$13.4M	—	—	—	n/m	—	89.93%	(1,364.28%)	Compare
BFRI Biofrontera Inc.	$12.3M	— (loss-making)	— (loss-making)	+32.92% (above 0%: growing)	n/m	+45.57% (above 0%: growing)	79.92%	(4.37%)	Compare
Median of peers	$25.6M	—	—	−0.57%	—	+45.57%	72.28%	(5.39%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 3 November 2025

Ownership

Directors and executive officers, together 1.70%

Rubric Capital Management LP 25.50%

Clearline Capital LP 5.50%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement